biomarkers – Medxy AI

Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation

By MedXY 05/15/2026

This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality in patients with atrial fibrillation.

Cardiology news Pathology & Lab Medicine/Bệnh học

Why the cTnI/cTnT Ratio May Matter: A New Signal for Distinguishing Acute Necrotic From Chronic Myocardial Injury

By MedXY 05/12/2026

A large multicohort and experimental study suggests the cTnI/cTnT ratio is biologically informative, separates acute from chronic myocardial injury, and modestly improves type 1 versus type 2 MI discrimination.

Critical Care news Respiratory

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure

By MedXY 05/05/2026

AHRF patients classified as hypoinflammatory are not prognostically uniform. Continuous biomarker-based probabilities reveal substantial mortality heterogeneity, especially below the binary 0.5 threshold, with implications for enrichment strategies in phenotype-guided critical care trials.

$Neurofilament Light Chain Reveals Rapid Neuroaxonal Injury in New-Onset Refractory Status Epilepticus$

Critical Care Neurology news

Neurofilament Light Chain Reveals Rapid Neuroaxonal Injury in New-Onset Refractory Status Epilepticus

By MedXY 04/30/2026

In a multinational cross-sectional study, serum and CSF neurofilament light chain—unlike S100B—tracked severe acute brain injury in cryptogenic NORSE, rose rapidly over the first 3 weeks, and predicted poor short-term outcome, supporting urgent neuroprotective treatment.

Neurology news Pathology & Lab Medicine

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

By MedXY 04/28/2026

Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.

Critical Care Infectious Diseases news

Biomarker Signatures in Sepsis: Linking Host Response to Clinical Outcomes

By MedXY 04/28/2026

A prospective cohort study identifies biomarker signatures for host resistance, disease tolerance, and damage in sepsis, revealing associations with mortality and sepsis subtypes.

Cardiology news Oncology

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients

By MedXY 04/22/2026

Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.

Clinical Updates Neurology news Pathology & Lab Medicine

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

By MedXY 04/07/2026

This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cognitive decline.

Gastroenterology news Oncology

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer

By MedXY 04/06/2026

A landmark multicohort study of 1,168 individuals reveals that gut microbiome diversity systematically declines across liver disease stages, with specific bacterial markers like Veillonella and functional metabolic shifts predicting disease progression and mortality risk.

Cardiology news

Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters

By MedXY 04/05/2026

A groundbreaking mass spectrometry study analyzing 486 heart failure patients and 98 controls identified over 21,000 unique peptides, revealing 1,924 differentially expressed peptides. The research highlights angiotensin-related peptides, natriuretic peptide pathways, and cardiometabolic regulators as key outcome predictors, while identifying three distinct patient clusters with varying survival probabilities.

Cardiology Clinical Updates Diabetes & Endocrinology news

Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis

By MedXY 03/31/2026

This review synthesizes recent evidence identifying MR-proADM as a premier prognostic biomarker in ATTR-CM, demonstrating its ability to outperform traditional natriuretic peptides and enhance existing clinical staging systems.

Cardiology Clinical Updates news

Advancing Venous Thromboembolism Prediction: Insights from Large-Scale Plasma Proteomics and Mendelian Randomization

By MedXY 03/31/2026

This review synthesizes findings from a landmark proteomic study identifying 23 plasma proteins associated with VTE risk, highlighting novel pathways in immunity and vascular senescence while exploring causal links through Mendelian Randomization.

Cardiology Hematology-Oncology news

Beyond the Clot: Novel Proteomic Markers Reveal New Pathophysiological Pathways for Venous Thromboembolism

By MedXY 03/31/2026

A large-scale proteomic meta-analysis across five cohorts identified 15 novel plasma protein markers for venous thromboembolism, highlighting the roles of the extracellular matrix, immunity, and vascular senescence in disease risk and offering potential new targets for clinical prevention.

Cardiology Hematology-Oncology news

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

By MedXY 03/28/2026

This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation pathways.

Cardiology Diabetes & Endocrinology news

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

By MedXY 03/26/2026

Researchers from the ARIC study have identified five specific proteomic markers that uniquely predict heart failure risk in individuals with diabetes. These findings, including four novel proteins, suggest distinct pathophysiological pathways for diabetic cardiomyopathy and offer new targets for precision screening and therapeutic intervention.

Clinical Updates Gastroenterology news

Temporal Dynamics of the Circulating Cytokinome in Severe Alcohol-Associated Hepatitis: A Longitudinal Clinical Analysis

By MedXY 03/23/2026

This review analyzes the longitudinal kinetics of 43 inflammatory biomarkers in patients with severe alcohol-associated hepatitis, comparing IL-1 receptor antagonism and corticosteroid therapy, highlighting treatment-specific signatures and the persistence of immune dysregulation.

Cardiology Clinical Updates Diabetes & Endocrinology news

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

By MedXY 03/22/2026

A comprehensive review of the ARIC study's identification of five unique proteomic markers—four novel—that specifically predict heart failure risk in patients with diabetes, offering new insights into lipid metabolism and inflammatory pathways.

Cardiology Clinical Updates news

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference

By MedXY 03/17/2026

This review synthesizes cutting-edge findings from multi-ethnic longitudinal cohorts using high-throughput proteomics to identify novel biomarkers and causal pathways for venous thromboembolism, moving beyond traditional clotting factors.

Neurology news

High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD

By MedXY 03/11/2026

A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammatory mimics like MOGAD and NMOSD, even in seronegative cases.

Cardiology Clinical Updates news

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

By MedXY 03/10/2026

This review synthesizes findings on how pregnancy biomarkers, particularly sFlt-1 and hs-cTnI, serve as early indicators of long-term maternal cardiovascular risk, offering a unique window for sex-specific prevention.